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Introduction
Pancreatic neuroendocrine tumours are uncommon malig-
nancies originating from the neural crest cells, with an
annual incidence of five cases per million population. Up
to 75% of these tumours are functioning [1], i.e. they
secrete various biologically active peptides responsible for
specific clinical syndromes [2]. The remainder (at least
25%) are non-functioning. They tend to behave more
aggressively, but as their growth is generally indolent, all
neuroendocrine tumours carry a much better prognosis
than ductal carcinoma of the pancreas [1].
The rare hypersecretion of parathyroid hormone-
related peptide (PTH-rP) by islet cell tumours produces
hypercalcaemia, which greatly complicates the patient’s
clinical course [3–5]. There are 31 reported cases of
PTH-rPoma in the world literature. This paper reports
another two patients with malignant hypercalcaemia due to
excessive PTH-rP production by pancreatic neuroendocrine
tumours. The clinical details of the second patient have
been described previously [6], but the immunohistochem-
istry has now been reviewed in the light of the first case.
Case no. 1
A 33-year-old woman presented in August 1995 with left
upper quadrant pain and a palpable abdominal mass associ-
ated with symptomatic hypercalcaemia (3.2 mmol/L,
normal 2.1–2.6 mmol/L) but a normal serum level of
parathormone (PTH) (2.8 pmol/L, normal 1.10–6.80
pmol/L). She was treated with intravenous fluids and
pamidronate. Computed tomography (CT) scan revealed
an 11.5-cm mass arising from the tail of the pancreas with
three liver deposits and nephrocalcinosis (Figure 1).
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Background
Hypercalcaemia is a common paraneoplastic syndrome. In
the context of pancreatic neuroendocrine tumours, it is
occasionally caused by secretion of parathyroid hormone-
related peptide (PTH-rP).
Case outlines
Two patients are reported in whom persistent hypercal-
caemia was traced to a large neuroendocrine pancreatic
tumour hypersecreting PTH-rP. Resection of the tumour
reduced serum levels of calcium and PTH-rP transiently in
each case until the patient developed bulky metastatic
disease. A 33-year-old woman remained hypercalcaemic
after the removal of all four hyperplastic parathyroid glands
had rendered circulating parathormone levels undetect-
able. Radical distal pancreatectomy was followed over the
next 4 years by operative debulking of liver metastases,
multiple hepatic artery embolisations , octreotide injections
and repeated admissions for intravenous fluid and biphos-
phonate therapy.A 41-year-old man presented with hyper-
calcaemia as well as features of somatostatinoma syndrome.
Symptomatic improvement after radical distal pancreatec-
tomy was short-lived, and hepatic artery embolisation
failed to control his rapidly progressive disease.
Discussion
Malignant hypercalcaemia associated with a neuro-
endocrine pancreatic tumour hypersecreting PTH-rP is
difficult to treat and can be life-threatening . Aggressive
surgical treatment is recommended initially, while somato-
statin analogues and hepatic artery embolisation are alter-
native therapeutic options for metastatic disease.
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Angiography (Figure 2) and CT-guided biopsy confirmed
the typical appearance of an endocrine tumour of the
pancreas. Ultrasound scan of the neck revealed two masses
of 4 mm and 5 mm in diameter located inferior to the right
and superior to the left thyroid lobe respectively. A diagno-
sis of multiple endocrine neoplasia type I (MEN I) was
made, but removal of all four (hyperplastic) parathyroid
glands failed to cure the hypercalcaemia. Her postoperative
PTH levels became undetectable, while serum PTH-rP was
elevated at 4.0 pmol/L (normal <0.5 pmol/L). 
In January 1996 the enormous pancreatic tumour was
removed by means of distal pancreatectomy en bloc with
spleen and adherent stomach. In addition, the largest of the
liver metastases was injected with alcohol. Immediately
postoperatively her serum calcium returned to normal
(2.2 mmol/L). Histological examination showed a malig-
nant neuroendocrine tumour, with nests of polygonal cells
and a focal trabecular and glandular pattern. Infiltration
into the splenic parenchyma, prominent lymphatic
involvement and vascular invasion were noted.
Immunohistochemical staining was positive for PTH-rP
(Figure 3) as well as neuron-specific enolase (NSE), synap-
tophysin, chromogranin and somatostatin. It was negative
for pancreatic polypeptide, insulin, gastrin, glucagon and
vasoactive intestinal polypeptide (VIP). 
The patient remained well and normocalcaemic for 18
months until nausea and vomiting developed and recurrent
hypercalcaemia was found; hepatic artery embolisation
failed to improve matters. PTH-rP level at that time was
1.6 pmol/L. In June 1998 she underwent removal of most of
the liver mass via an extended right hepatectomy, plus a
metastatic nodule attached to the splenic flexure of colon.
Reoperation for reactive haemorrhage was followed by
staphylococcal pneumonia requiring percutaneous trache-
ostomy, but eventually she was discharged home in good
health at 6 weeks.
The patient continued to have symptomatic and
intractable hypercalcaemia, requiring frequent admissions
for intravenous rehydration and biphosphonate therapy.
Repeat transcatheter embolisation of hepatic metastases in
September 1998 was more successful than before in con-
trolling this problem until August 1999, when multiple
bony metastases (spine, pelvis: Figure 4) were treated with
external beam radiotherapy to control pain. Serum PTH-rP
measurement (April 2000) remained elevated at 2.2
pmol/L. Slow-release octreotide was started to control
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Figure 1. Case no. 1: computed tomography showing the presence of three
liver metastases.
Figure 2. Case no. 1: coeliac angiogram showing the ‘blush’ of a large tumour
in the body of the pancreas plus one liver metastatic deposit.
Figure 3. Case no. 1: photomicrograph of the pancreatic tumour showing an
acinus and its adjacent duct, with positive (brown) staining for PTH-rP (original
magnification 3400).
recurrent hypercalcaemia (3.35–3.21 mmol/L) plus two
further hepatic artery embolisations during late 2000.
Targeted octreotide therapy is now being considered since
scintigraphy shows plentiful somatostatin receptors within
the metastatic deposits.
Case no. 2
During an open cholecystectomy for gallstones, multiple
liver metastases were discovered in a 41-year-old man.
Biopsies showed neuroendocrine tumour and CT scan
revealed a lesion in the pancreatic tail. Thereafter the
patient declined conventional medical treatment and was
lost to follow-up, but 4 years later he developed sympto-
matic hypercalcaemia (4.5 mmol/L) with undetectable
serum PTH but elevated levels of PTH-rP (7.8 pmol/L) and
somatostatin (774 pmol/L: normal <100 pmol/L). Hepatic
artery embolisation produced only temporary control. One
year later radical distal pancreatectomy was undertaken for
a 20-cm tumour with en bloc excision of the spleen, left kid-
ney, adrenal and colon. He recovered well with falls in
PTH-rP (1.1 pmol/L) and calcium (2.8 mmol/L), but per-
sistent elevation of somatostatin (1141 pmol/L).
Histological examination showed typical features of a pan-
creatic neuroendocrine tumour with vascular invasion and
lymph node involvement. Immunohistological staining was
positive for NSE, chromogranin, somatostatin and PTH-rP.
It was negative for pancreatic polypeptide, insulin and VIP.
Four months postoperatively he developed seizures due to
recurrent hypercalcaemia (and tumour) and died soon
afterwards. 
Discussion 
Hypercalcaemia is one of the most frequent types of para-
neoplastic syndrome [7,8]. Malignant hypercalcaemia can
be classified as local osteolytic, resulting from bone resorp-
tion mediated by primary or metastatic tumour cells, or
hormonal, mediated by humoral factors such as PTH-rP [8].
Hypercalcaemia associated with endocrine pancreatic
tumours is commonly due to primary hyperparathyroidism,
with elevated serum PTH levels as part of multiple
endocrine neoplasia type I [9]. Hypercalcaemia is a rare
feature of islet cell carcinoma of the pancreas, although
many such patients have increased serum levels of PTH-rP
with normal levels of PTH [3]; this combination discrimi-
nates between primary hyperparathyroidism and
PTH-rPoma [3,10]. Both our patients presented with a
neuroendocrine pancreatic tumour, hypercalcaemia and
increased serum PTH-rP level. Immunohistochemical
staining was positive in each case, and one patient (case no.
2) developed concomitant features of somatostatinoma
(gallstones and mild diabetes). 
PTH-rP is a single-chain peptide, and its amino termi-
nal domain has considerable similarity to PTH [3]. The
PTH-rP gene is located on human chromosome 12 and is
thought to belong to the same gene family as PTH [11].
PTH-rP is expressed in response to a variety of physiologi-
cal stimuli and acts as an autocrine, paracrine and
endocrine peptide involving calcium translocation and/or
signalling [12]. If PTH-rP is produced in excess, it exerts an
endocrine effect by interacting with the classical bone and
kidney PTH-receptor leading to the humoral hypercal-
caemia of malignancy [13]. Serum PTH-rP level can be
used as a tumour marker to indicate treatment effectiveness
and disease progression (as in both our patients) [3]. 
A search of the world literature has revealed 31 previ-
ously reported patients [3–6,9,10,14–28] (Table 1), in
whom endocrine pancreatic tumours have been associated
with humoral hypercalcaemia of malignancy due to
PTH-rP hypersecretion. As in our cases, these tumours show
a predilection for young people (median age 44.5 years,
range 8–77 years) and have an equal sex distribution (M:F =
15:17). They tend to be large (median diameter 10 cm);
they arise within the tail of pancreas (53%), body (32%) or
head (16%). They are slow-growing. From available data,
223
Parathyroid hormone-related peptide
Figure 4. Case no. 1: bone scan showing bony metastases in the pelvis.
24 patients were alive at a median 6.9 year follow-up. For
the other eight patients who died, the median survival time
was 6.6 years. Metastatic spread (in 81% of patients) was
usually to the liver (n=26) but also to the spleen (four),
regional lymph nodes (four), left kidney (two) and (once
each) bone, pleura and colon. 
Management of the humoral hypercalcaemia of malig-
nancy is aimed at the control of serum calcium, preferably
by removal of the tumour [10], but alternatively by pharma-
cological means including forced diuresis and agents such
as calcitonin, plicamycin, biphosphonates, gallium nitrate
or glucocorticoids [29]. Pancreatectomy was feasible in 13
of 23 patients with available data, and resection was associ-
ated with decreased serum PTH-rP and serum calcium
levels [5,6,16]. Palliative chemotherapy (streptozotocin, 5-
fluorouracil, a -interferon, steroids) was given alone in six
patients and after resection in two. Somatostatin analogues
(octreotide, lanreotide) have recently been introduced and
proved useful in one of our patients (case no. 1), as well as
in another four reported cases [9,10,14]. Hepatic artery
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Table 1. Details of 32 patients with neuroendocrine pancreatic carcinoma associated with hypercalcaemia
Patient Sex Age Size Location Metastases Surgical Other Reference
no. (yr) (cm) resection treatment no.
1 M 57 10 B L – SZT 18
2 M 8 * * L PP – 19
3 F 62 * * L – SZT 20
4 F 60 10 T L – 5-FU+ SZT 4
5 M 41 14 H L PP HAE 21
6 F 47 9 B Nil TP – 22
7 M 44 * * L * 23
8 F 37 5 T L – SA 9
9 F 42 >10 B L – SA 24
10 M 30 8 T L DP – 5
11 F 60 >10 H L – a -INF 5
12 M 45 12 T Nil DP SZT 25
13 F 77 * T L DP SZT 26
14 F 47 11 T L DP – 16
15 M 30 * B Nil – SZT 27
16 M 41 18 * L PP – 15
17 M 43 15 B L DP – 15
18 M 64 7 T L, K, P, LN – Steroids 15
19 F 39 12 B LN PP – 28
20 M 36 * * L, S – HAE 17
21 F 75 8 T Nil – SA 10
22 F 45 3 H L W SA 14
23 F 42 * * L, S * 3
24 F 45 * * L * 3
25 M 64 * * L * 3
26 M 61 * * Nil * 3
27 F 38 * * L * 3
28 M 20 * * L * 3
29 F 47 * * L * 3
30 F 51 * * L * 3
31 M 41 20 T L, K, S, C,LN DP HAE 6
32 F 33 11 T L, S, Bo, LN DP HAE, SA †
H = head; B = body;T = tail; L = liver; S = spleen; K = kidney; C = colon; P = pleura; LN = lymph nodes; Bo = bone; PP = partial pancreatectomy; DP = distal
pancreatectomy;TP = total pancreatectomy;W = Whipple’s procedure; SZT = streptozotocin; 5-FU = 5-fluorouracil; a -INF = a -interferon; SA = somatostatin
analogues; HAE = hepatic artery embolisation.
*Unknown.
†Case no. 1.
embolisation offers another means of controlling hypercal-
caemia related to liver metastases that was used in three
patients [6,17]. Both our patients underwent resection of
large cancers of the distal pancreas with resultant reduction
in serum PTH-rP levels, and both had subsequent hepatic
artery embolisation in an attempt to control the symptoms
of recurrent disease. One patient is alive with multiple
metastases, but the other died four months postoperatively
from widespread disease.
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